C4A and infection: Given the association between CD and immune responses 18 and the poor tolerability of standard BNZ treatment regimens in humans 54,55, we then assessed whether an experimental regimen consisting of a combination of reduced-dose BNZ (25 mg/kg for 18 days) followed by two doses of a therapeutic vaccine, Tc24 C4 (25 μg at days 92 and 106 post-infection), could provide a phenotypic and metabolic benefit.